Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Quidel — 34th Annual J.P. Morgan Healthcare Conference (January 2016)
11 slides from Quidelortho's conference presentation, Jan 13, 2016
Slide 1: Investor Presentation
Investor Presentation Doug Bryant 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actu
Slide 3: Our Strategic Intent (The What)
Our Strategic Intent (The What) Build a broader-based diagnostic company that delivers revenue and margin more consistently. Use existing resources to solidify price and volume in our core businesses, while gaining access to, and competing in larger markets, to include molecular. 3
Slide 4: Our Strategy (The How)
Our Strategy (The How) Defend and grow our core business • Sofia 2 Influenza, RSV and GAS • Virena data management • Sofia Strep Read Now • Sofia hCG • Additional focus on emerging U.S. health care markets Diversify • Convert GAS culture to same-day confirmation (Solana GAS) • Sofia Vitamin D • Sofi
Slide 5: Key Initiatives: Replace Strep A culture testing
Key Initiatives Replace back-up Strep A culture testing with Solana and AmpliVue Group A Strep • Approximately 37 million negative rapid Strep tests are cultured to confirm a negative result; only 10% are positive. • In the infectious disease community, patient satisfaction and antibiotic stewardshi
Slide 6: Key Initiatives: Grow the U.S. influenza testing market
Key Initiatives Grow the U.S. influenza testing market (and gain share) by providing better information • Statistically significant number of users submitting de-identified Sofia Influenza A+B test data to Virena cloud. • Intend to create a Quidel Ecosystem of Virena users and change the way we comp
Slide 7: Key Initiatives: Grow the U.S. influenza testing market
Key Initiatives Grow the U.S. influenza testing market (and gain share) by providing better information • With launch of Sofia 2, our influenza users will see an improvement in individual test performance and workflow - Sofia 2 optics provide added performance benefits. - Kinetic reading enables pos
Slide 8: We are on a path to our longer term financial objectives
We are on a path to our longer term financial objectives 1. Achieve low- to mid-teens in annual revenue growth through new product introductions. 2. Invest in the development and commercialization of new products driving gross margins to exceed 65%. 3. Leverage operational efficiency driving EBITDA
Slide 9: Quidel financial overview
Quidel financial overview Revenue Adjusted EBITDA (1) (in $ million, percent gross margin in white) (adjusted, in $ million) $50.0 $250 120% $44.9 $45.0 $40.6 $40.9 $207.7 $38.9 100% $40.0 $200 $182.6 $175.4 $35.0 $158.6 $155.7 80% $27.9 $30.0 $150 $113.3 $25.0 60% $20.0 $100 60% 61% 62% 59% 54% 40%
Slide 10: 2015 expected operating cost structure
2015 expected operating cost structure Annual Investment: R&D Annual Investment: S&M (in $ million; percentage of sales in white) (in $ million; percentage of sales in white) $50 Range 65% $45 65% $45-$47 $45 $40 Range $37.9 $41.5 55% $35-$37 55% $40 $35 $34.2 45% $35 $33.8 45% $30 $27.7 $30.3 $26.3
Slide 11: Growth drivers and near-term milestones
Growth drivers and near-term milestones • Continue to pursue inorganic opportunities to augment the non- respiratory part of the business. • Aim for 65% Gross Margin, 15% operating margin in 2016. • Grow Sofia installed base with Sofia, Sofia 2 and gain market share. • Increase the number of Virena
Quidel — 34th Annual J.P. Morgan Healthcare Conference (January 2016) on 6ix